Tryp Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jason Carroll

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.7yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

Companies Like Tryp Therapeutics (CSE:TRYP) Are In A Position To Invest In Growth

Aug 02

CEO

Jason Carroll

less than a year

Tenure

Mr. Jason Carroll serves as Chief Executive Officer of Tryp Therapeutics Inc. since October 01, 2023 and serves as its Director. He has a wealth of experience as a highly regarded life sciences executive,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Kuo	Co-Founder & Director	no data	CA$26.67k	6.22% CA$ 360.0k
Peter Molloy	Chief Business Officer & Director	less than a year	CA$183.59k	0.21% CA$ 12.0k
Jason Carroll	CEO & Director	less than a year	no data	no data
James Gilligan	President & Chief Scientific Officer	3.5yrs	CA$315.87k	no data
William Garner	Founder & MD	no data	CA$56.43k	39.85% CA$ 2.3m
Jim O'Neill	Chief Financial Officer	1.7yrs	no data	no data
Sidney Taubenfeld	Chief Operating Officer	1.9yrs	CA$48.70k	no data
Joy Willis	Director of Investor Relations	2.7yrs	no data	no data
Michael Silverman	Chief Medical Officer	1.4yrs	no data	no data

1.7yrs

Average Tenure

58yo

Average Age

Experienced Management: TRYP's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
James Kuo	Co-Founder & Director	4.7yrs	CA$26.67k	6.22% CA$ 360.0k
Peter Molloy	Chief Business Officer & Director	no data	CA$183.59k	0.21% CA$ 12.0k
Jason Carroll	CEO & Director	no data	no data	no data
William Schmidt	Member of Scientific Advisory Board	3.3yrs	no data	no data
P. Jull	Independent Chairman of the Board	3.7yrs	CA$26.67k	0.48% CA$ 27.8k
Christopher Ntoumenopoulos	Independent Non Executive Director	2yrs	no data	no data
Daniel Clauw	Member of Scientific Advisory Board	2.8yrs	no data	no data
Robin Carhart-Harris	Chairman of Scientific Advisory Board	3.3yrs	no data	no data
Rachel Wevrick	Member of Scientific Advisory Board	no data	no data	no data
Derek Ott	Member of Scientific Advisory Board	no data	no data	no data
Joel Castellanos	Member of Scientific Advisory Board	3.3yrs	no data	no data

3.3yrs

Average Tenure

58yo

Average Age

Experienced Board: TRYP's board of directors are considered experienced (3.3 years average tenure).

Tryp Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Less than half of directors are independent

Less than half of directors are independent

Tryp Therapeutics Inc., Annual General Meeting, Feb 16, 2024

Tryp Therapeutics Announces Appointment of Jason Carroll as New Chief Executive Officer, Effective October 1, 2023

Tryp Therapeutics Inc. Announces the Passing of David Tousley, Director

Tryp Therapeutics Appoints Jim O'Neill as Chief Financial Officer

Recent updates

Tryp Therapeutics to be Delisted from the Canadian Securities Exchange and to Stop Trading on the OTCQB Venture Market Following the Arrangement

Tryp Therapeutics Inc. (CNSX:TRYP) completed the acquisition of Exopharm Limited (ASX:EX1) in a reverse merger transaction.

Less than half of directors are independent

Less than half of directors are independent

Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting

Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting

New major risk - Financial position

Tryp Therapeutics Inc., Annual General Meeting, Feb 16, 2024

Exopharm Limited (ASX:EX1) entered into a definitive agreement to acquire Tryp Therapeutics Inc. (CNSX:TRYP) for CAD 7.2 million.

Exopharm Limited (ASX:EX1) entered into a definitive agreement to acquire Tryp Therapeutics Inc. (CNSX:TRYP) for CAD 7.2 million.

Tryp Therapeutics Inc. announced that it has received AUD 3.215 million in funding

Tryp Therapeutics Inc. announced that it has received AUD 0.175 million in funding

Tryp Therapeutics Inc. announced that it expects to receive AUD 0.175 million in funding

Tryp Therapeutics Announces Appointment of Jason Carroll as New Chief Executive Officer, Effective October 1, 2023

Tryp Therapeutics Inc. Announces the Passing of David Tousley, Director

Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients with IBS at Massachusetts General Hospital

Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder with Psilocybin-Assisted Psychotherapy

Price target decreased to CA$1.50

Tryp Therapeutics Inc. Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

Tryp Therapeutics, Inc. Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803

Tryp Therapeutics Appoints Jim O'Neill as Chief Financial Officer

High number of new and inexperienced directors

Tryp Therapeutics Inc. Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

Tryp Therapeutics Appoints Sid Taubenfeld as Chief Operating Officer

Tryp Therapeutics Inc. Announces Results of First Patient Dosed in its Phase II Clinical Trial for the Treatment of Binge Eating Disorder

Tryp Therapeutics Inc. Appoints Chris Ntoumenopoulos to Board of Directors

Price target decreased to CA$1.50

Tryp Therapeutics Inc., Annual General Meeting, Jun 23, 2022

Insider recently bought CA$1.0m worth of stock

Tryp Therapeutics Inc. Announces Board Changes

Tryp Therapeutics Inc. announced that it expects to receive CAD 2 million in funding

Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder

Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia

Tryp Therapeutics Submits IND Application for Phase 2A Clinical Trial in Eating Disorders

Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida

MD, Founder & Executive Director recently bought CA$65k worth of stock

Companies Like Tryp Therapeutics (CSE:TRYP) Are In A Position To Invest In Growth

Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Tryp Therapeutics Inc. Appoints Luke Hayes as Chief Financial Officer

Tryp Therapeutics Inc. announced that it has received CAD 2 million in funding

Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor

Tryp Therapeutics Plans Phase 2A Eating Disorder Clinical Trial with Dr. Jennifer Miller

Tryp Therapeutics Inc. announced that it expects to receive CAD 2 million in funding

Tryp Therapeutics Announces the Appointment of Greg Mckee as Executive Chairman

Tryp Therapeutics Inc. Appoints Robin Carhart Harris to Scientific Advisory Board

Tryp Therapeutics Inc., Annual General Meeting, Mar 24, 2021

Tryp Therapeutics Inc. Appoints Gregory M. Mckee to the Board of Directors

Tryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory Board

Tryp Therapeutics Inc. Appoints Dr. Peter Guzzo as Its Vice President of Drug Development

Tryp Therapeutics Inc. has completed an IPO in the amount of CAD 4.35 million.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age